2. 筋萎縮性側索硬化症 [臨床試験数:508,薬物数:530(DrugBank:146),標的遺伝子数:170,標的パスウェイ数:221

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-020257-13-IT30/07/201005/07/2010A pilot, prospective, randomized, open, blinded end point, phase II study of tolerability and efficacy of Eperisone in Amyotrophic Lateral Sclerosis - EPERISONE AND ALSA pilot, prospective, randomized, open, blinded end point, phase II study of tolerability and efficacy of Eperisone in Amyotrophic Lateral Sclerosis - EPERISONE AND ALS PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
MedDRA version: 9.1Level: SOCClassification code 10029205
Trade Name: MYONAL*30CPR RIV 100MG
INN or Proposed INN: EPERISONE
Trade Name: LIORESAL*50CPR 10MG
INN or Proposed INN: Baclofen
AZIENDA OSPEDALIERO-UNIVERSITARIANULLNot RecruitingFemale: yes
Male: yes
Phase 2Italy